GT Biopharma Inc (GTBP NASDAQ) stock market data APIs
$0.4759
-0.03(-6.3%)
as of May 29, 2026
Try our APIs with
free plan!
GT Biopharma Inc Financial Data Overview
Price chart is built with
Anychart
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Prev. Close
0.4759
Open
0.4493
High
0.4943
Low
0.4472
52 wk Range
0.261-3.85
Market Cap
17 245 K
Shares Outstanding
36 063 K
EPS
-0.11
Beta
0.637
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GT Biopharma Inc data using free add-ons & libraries
Get GT Biopharma Inc Fundamental Data
GT Biopharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -6 760 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-31
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GT Biopharma Inc News
New
GT Biopharma Records Q1 Loss Of $2 Mln; Advances GTB-3650 In Phase 1 Trial For Leukemia
(RTTNews) - GT Biopharma Inc. (GTBP), a clinical-stage immuno-oncology company, on Friday announced first quarter results and provided updates on its developing pipeline. The company is advancing can...
"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming Therapies
Issued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tu...
GT Biopharma Reports Full Year 2025 Financial Results
Phase 1trial evaluating GTB-3650TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating G...
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
VANCOUVER, British Columbia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Equity InsiderMarket Intelligence Brief – The 2026 economy has hit the wall of physical limits. After a decade of rewarding "potenti...
Get GT Biopharma Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
